Truist Financial
LCTX icon

Truist Financial’s Lineage Cell Therapeutics LCTX Stock Holding History

Truist Financial’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-42,591
Closed -$63.9K – 2627
2023
Q1 		$63.9K Buy
+42,591
New +$59.4K ﹤0.01% 2528

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Truist Financial's LCTX Position: Q2 2023 in Review

Truist Financial sold out of Lineage Cell Therapeutics (LCTX) in Q2 2023, closing a stake of 42,591 shares — an estimated $63.9K sold.

Truist Financial first reported a position in LCTX in Q1 2023 and held it in 1 quarter. The position peaked at $63.9K in Q1 2023. 107 funds tracked by Wall St. Rank hold LCTX as of Q2 2023.

  • Truist Financial reported no remaining Lineage Cell Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Truist Financial sold 42,591 Lineage Cell Therapeutics shares in Q2 2023, an estimated $63.9K.
  • Truist Financial first reported a position in Lineage Cell Therapeutics in Q1 2023 and held it in 1 quarter.
  • Truist Financial's Lineage Cell Therapeutics position peaked at $63.9K in Q1 2023.
  • 107 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2023.

Based on Truist Financial's 13F filing for Q2 2023, filed 1 Aug 2023.